Abstract
Since 2010 the 13-valent pneumococcal conjugate vaccine (PCV13) replaced the 7-valent vaccine (PCV7) as the leading pneumococcal vaccine used in children through the private sector. Although, neither of the PCVs were used significantly in adults, changes in adult invasive pneumococcal disease (IPD) were expected due to herd protection. We characterized n = 1163 isolates recovered from IPD in adults in 2012–2014 with the goal of documenting possible changes in serotype prevalence and antimicrobial resistance. Among the 54 different serotypes detected, the most frequent, accounting for half of all IPD, were serotypes: 3 (14%), 8 (11%), 19A (7%), 22F (7%), 14 (6%), and 7F (5%). The proportion of IPD caused by PCV7 serotypes remained stable during the study period (14%), but was smaller than in the previous period (19% in 2009–2011, p = 0.003). The proportion of IPD caused by PCV13 serotypes decreased from 51% in 2012 to 38% in 2014 (p < 0.001), mainly due to decreases in serotypes 7F and 19A. However, PCV13 serotype 3 remained relatively stable and the most frequent cause of adult IPD. Non-PCV13 serotypes continued the increase initiated in the late post-PCV7 period, with serotypes 8 and 22F being the most important emerging serotypes. Serotype 15A increased in 2012–2014 (0.7% to 3.5%, p = 0.011) and was strongly associated with antimicrobial resistance. However, the decreases in resistant isolates among serotypes 14 and 19A led to an overall decrease in penicillin non-susceptibility (from 17 to 13%, p = 0.174) and erythromycin resistance (from 19 to 13%, p = 0.034). Introduction of PCV13 in the NIP for children, as well as its availability for adults may further alter the serotypes causing IPD in adults in Portugal and lead to changes in the proportion of resistant isolates.
Highlights
Two types of pneumococcal vaccines are licensed to prevent invasive pneumococcal disease (IPD), both targeting a restricted number of serotypes out of the 94 serotypes currently recognized in Streptococcus pneumoniae: strictly polysaccharide based vaccines and polysaccharide-protein conjugate based vaccines (PCVs) (Ramirez, 2014)
In spite of the gradual increase in PCV uptake in children and the relatively modest coverage, we found significant changes in serotype distribution and antimicrobial susceptibility of pneumococci causing adult IPD that could be attributed at least in part to herd protection
When considering serotypes presenting three or more cerebral spinal fluid (CSF) isolates, we found a positive association with CSF for serotypes 19F (p = 0.006) and 23B (p = 0.005), both significant after false discovery rate (FDR) correction (Table S1)
Summary
Two types of pneumococcal vaccines are licensed to prevent invasive pneumococcal disease (IPD), both targeting a restricted number of serotypes out of the 94 serotypes currently recognized in Streptococcus pneumoniae: strictly polysaccharide based vaccines and polysaccharide-protein conjugate based vaccines (PCVs) (Ramirez, 2014). A 23-valent strictly polysaccharide vaccine (PPV23) includes 12 of the serotypes found in PCV13 (except 6A) and serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F. This vaccine has been used for two decades in older children and adults and has proven efficacy in the prevention of IPD (Moberley et al, 2013)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
